High dose of antithrombin III induces indefinite survival of fully allogeneic cardiac grafts and generates regulatory cells

    loading  Checking for direct PDF access through Ovid

Abstract

Background.

The authors investigated whether antithrombin III (AT-III) could induce unresponsiveness to alloantigens.

Methods.

CBA mice were given intravenous injection of 50 or 500 U/kg AT-III or control plasma the same day as transplantation of a heart from a C57BL/6 mouse. An adoptive transfer study and mixed leukocyte culture analysis were also performed.

Results.

Naive CBA mice rejected C57BL/6 cardiac grafts acutely (median survival time [MST], 9 days). The 50-U/kg dose of AT-III induced a moderate increase in graft survival (MST, 25 days), whereas control mice rejected their graft acutely (MST, 7 days). With the 500-U/kg dose of AT-III, all grafts survived indefinitely (>100 days) and regulatory cells were generated. In vitro, AT-III suppressed proliferation of mixed leukocyte responses and generation of interleukin-2.

Conclusion.

AT-III can be not only an antithrombotic agent but also a strong immunomodulating agent when used at high dose.

Related Topics

    loading  Loading Related Articles